Clinical Trial Update: Gene Therapy in Treating Patients With Unresectable, Recurrent, or Refractory Head and Neck Cancer [Phase 1, Phase 2]

View source ↗

Summary

A completed Phase 1/2 gene therapy trial in patients with unresectable, recurrent, or refractory head and neck cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Head and Neck Cancer

Snippet

Sponsor: Dana-Farber Cancer Institute | Conditions: Head and Neck Cancer | Phase 1, Phase 2 | Status: COMPLETED